AptarGroup (ATR)
(Delayed Data from NYSE)
$174.71 USD
+1.55 (0.90%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $174.72 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$174.71 USD
+1.55 (0.90%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $174.72 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
GPK vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GPK vs. ATR: Which Stock Is the Better Value Option?
Avery Dennison (AVY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Avery Dennison (AVY) reports year-over-year improvement in fourth-quarter 2020 earnings on cost saving initiatives and improving demand. It also expects to deliver improvement in fiscal 2021 results.
Honeywell (HON) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Honeywell's (HON) fourth-quarter 2020 revenues decline 6% year over year on account of lacklustre performance across Aerospace and Performance Materials and Technologies segments.
A. O. Smith (AOS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
A. O. Smith's (AOS) fourth-quarter 2020 net sales increase 11.1% year over year on solid performance across both of its segments.
Tetra Tech (TTEK) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Tetra Tech's (TTEK) first-quarter fiscal 2021 net revenues fall 1.5%, on account of weak performance of its Commercial / International Services Group segment.
Cimpress (CMPR) Q2 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Lackluster performance across its National Pen and Upload and Print segments hurts Cimpress (CMPR) second-quarter fiscal 2021 revenues.
3M's (MMM) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
3M's (MMM) fourth-quarter 2020 net sales increase 5.8% year over year on account of impressive performance across its segments.
Crane (CR) Q4 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Crane's (CR) fourth-quarter 2020 net sales decrease 13.4% year over year largely due to the coronavirus outbreak-led issues, partially offset by positive impact from acquisitions and foreign exchange.
iRobot (IRBT) Gains From Solid Product Portfolio Amid Cost Woes
by Zacks Equity Research
iRobot (IRBT) benefits from its solid product portfolio, strong innovation capabilities and investments in building brand awareness. Pandemic-led uncertainties & high operating costs are concerns.
Berry Global (BERY) Displays Solid Prospects, Headwinds Persist
by Zacks Equity Research
Berry Global (BERY) stands to gain from strength across its end markets, acquired assets and strong cash flows. However, high costs and expenses along with huge debts pose concerns.
Here's Why AptarGroup (ATR) Stock is an Attractive Pick Now
by Zacks Equity Research
Demand for AptarGroup's (ATR) pharmaceutical products and sanitizers, liquid soaps and disinfectants makes the stock a prudent investment pick.
SON vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
SON vs. ATR: Which Stock Is the Better Value Option?
AptarGroup (ATR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Triggered by the pandemic, increasing demand for pharmaceutical products and sanitizers, liquid soaps and disinfectants featuring AptarGroup's (ATR) solutions is driving its shares.
AptarGroup (ATR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AptarGroup (ATR) Hits 52-Week High: What's Driving the Rally?
by Zacks Equity Research
Pandemic-induced demand for pharmaceutical products is likely to drive AptarGroup's (ATR) Pharma segment, while demand in personal care market and home care market will aid the Beauty + Home segment.
Here's Why You Should Hold On to AptarGroup (ATR) Stock Now
by Zacks Equity Research
Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.
AptarGroup (ATR) Q3 Earnings & Sales Top Estimates, Shares Up
by Zacks Equity Research
AptarGroup's (ATR) top and bottom lines improve on solid growth in the Pharma segment as well as in the food, personal care and home care markets during the July-September period.
PKG vs. ATR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PKG vs. ATR: Which Stock Is the Better Value Option?
AptarGroup (ATR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AptarGroup (ATR) delivered earnings and revenue surprises of 19.05% and 7.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
AptarGroup (ATR) Suffers From Weak End Markets Amid Pandemic
by Zacks Equity Research
AptarGroup's (ATR) third-quarter 2020 results are likely to reflect higher demand for pharmaceutical products amid the COVID-19 pandemic. However, weak beauty products sales will negate these gains.
Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline
by Zacks Equity Research
AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SON or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SON vs. ATR: Which Stock Is the Better Value Option?
All You Need to Know About AptarGroup (ATR) Rating Upgrade to Buy
by Zacks Equity Research
AptarGroup (ATR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BERY or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?
BERY or ATR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BERY vs. ATR: Which Stock Is the Better Value Option?